Published in Pharmacogenetics on February 01, 1997
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol (2009) 1.49
The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects. PLoS One (2015) 1.37
Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol (2002) 1.30
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet (2009) 1.17
Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol (2003) 1.08
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol (2008) 1.08
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics (2009) 1.06
CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet (2011) 1.05
NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. Eur J Clin Pharmacol (2010) 0.96
Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol (2005) 0.95
Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect (1999) 0.95
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol (1999) 0.94
Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol (2007) 0.90
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet (2013) 0.88
Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol (2010) 0.88
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol (2007) 0.87
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol (2004) 0.86
The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev (2006) 0.86
Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther (2009) 0.85
CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol (2000) 0.85
Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85
The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur J Clin Pharmacol (2005) 0.84
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J (2011) 0.84
Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci (2013) 0.84
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol (2005) 0.84
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol (2014) 0.83
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenomics Pers Med (2013) 0.83
Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol (2007) 0.83
Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay). BMC Clin Pharmacol (2006) 0.81
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug Des Devel Ther (2015) 0.81
Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism. Toxicology (2012) 0.80
Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution. BMC Evol Biol (2014) 0.79
Metabolism of profenofos to 4-bromo-2-chlorophenol, a specific and sensitive exposure biomarker. Toxicology (2013) 0.79
Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects. Antimicrob Agents Chemother (2015) 0.79
Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.79
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol (2009) 0.78
Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. Oman Med J (2013) 0.77
Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans. Yonsei Med J (2012) 0.77
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention. Vasc Health Risk Manag (2011) 0.77
Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol (2014) 0.76
Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. Br J Clin Pharmacol (2003) 0.76
Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. Lett Drug Des Discov (2016) 0.76
Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact (2014) 0.75
Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A (2012) 0.75
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene (2016) 0.75
CYP2C19 drug-drug and drug-gene interactions in ED patients. Am J Emerg Med (2015) 0.75
Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. Drugs R D (2017) 0.75
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (1997) 14.91
Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health (1993) 11.92
Focal contacts as mechanosensors: externally applied local mechanical force induces growth of focal contacts by an mDia1-dependent and ROCK-independent mechanism. J Cell Biol (2001) 9.73
Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science (1999) 7.12
An improved and simplified method of detecting the acetylator phenotype. J Med Genet (1969) 6.40
Natural history of mild cognitive impairment in older persons. Neurology (2002) 6.09
Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat Cell Biol (1999) 5.84
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology (2005) 5.76
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet (1980) 5.68
Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord (2001) 5.09
p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. EMBO J (1997) 5.03
A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med (2015) 4.95
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci (1991) 4.53
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Latent Semantic Indexing of medical diagnoses using UMLS semantic structures. Proc Annu Symp Comput Appl Med Care (1991) 4.09
An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med (1999) 3.76
Maintaining mobility in late life. I. Demographic characteristics and chronic conditions. Am J Epidemiol (1993) 3.74
Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology (2004) 3.61
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology (2003) 3.59
Role of citron kinase as a target of the small GTPase Rho in cytokinesis. Nature (1998) 3.55
Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med (1996) 3.48
Established populations for epidemiologic studies of the elderly: study design and methodology. Aging (Milano) (1993) 3.47
ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett (1996) 3.46
Weekend mortality for emergency admissions. A large, multicentre study. Qual Saf Health Care (2010) 3.45
Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology (2002) 3.40
Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br (1982) 3.39
The Jehovah's Witness and dementia: who or what defines 'best interests'? Anaesthesia (2006) 3.37
Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology (2003) 3.35
Age-specific incidence of Alzheimer's disease in a community population. JAMA (1995) 3.09
Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. Science (1996) 2.99
Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem (2000) 2.99
Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem (1996) 2.92
Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med (1992) 2.92
Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol (1998) 2.81
150 bicycle injuries in children: a comparison with accidents due to other causes. Injury (1981) 2.81
Cognitive activity and incident AD in a population-based sample of older persons. Neurology (2002) 2.77
Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychiatry (2004) 2.67
A prospective study of incident comprehensive medical home care use among the elderly. Am J Public Health (1988) 2.67
Social resources and cognitive decline in a population of older African Americans and whites. Neurology (2004) 2.66
Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. Clin Med (2006) 2.63
Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology (2003) 2.60
Campylobacteriosis in New Zealand: results of a case-control study. J Epidemiol Community Health (1997) 2.55
A novel partner for the GTP-bound forms of rho and rac. FEBS Lett (1995) 2.52
Structural and mechanistic insights into the interaction between Rho and mammalian Dia. Nature (2005) 2.52
Change in body mass index and risk of incident Alzheimer disease. Neurology (2005) 2.48
Tuberculin Testing in Children. Br Med J (1945) 2.48
Cognitive decline in incident Alzheimer disease in a community population. Neurology (2010) 2.41
Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol (1999) 2.39
Long-term outcomes of standard discectomy for lumbar disc herniation: a follow-up study of more than 10 years. Spine (Phila Pa 1976) (2001) 2.37
Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology (2003) 2.32
Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (1994) 2.32
Cognitive activity in older persons from a geographically defined population. J Gerontol B Psychol Sci Soc Sci (1999) 2.31
Correlates of cognitive function in an elderly community population. Am J Epidemiol (1988) 2.26
Chiral bis(oxazoline) copper(II) complexes: versatile catalysts for enantioselective cycloaddition, Aldol, Michael, and carbonyl ene reactions. Acc Chem Res (2000) 2.22
Age of Neoproterozoic bilatarian body and trace fossils, White Sea, Russia: implications for metazoan evolution. Science (2000) 2.21
Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol (2000) 2.19
Rho effectors and reorganization of actin cytoskeleton. FEBS Lett (1997) 2.19
Terminal decline in cognitive function. Neurology (2003) 2.18
Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther (1992) 2.18
Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N Engl J Med (2001) 2.15
Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. Oncogene (2000) 2.08
HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen's University HIV Prison Study Group. QJM (2000) 2.06
Cognitive activity and cognitive decline in a biracial community population. Neurology (2003) 2.06
The effect of applying NICE guidelines for the investigation of stable chest pain on out-patient cardiac services in the UK. QJM (2011) 2.02
Walking speed as a good predictor for the onset of functional dependence in a Japanese rural community population. Age Ageing (2000) 1.99
Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst (1998) 1.97
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology (2008) 1.97
Epidemiology of disability in the oldest old: methodologic issues and preliminary findings. Milbank Mem Fund Q Health Soc (1985) 1.94
Cadaveric study of movement of an unstable atlanto-axial (C1/C2) cervical segment during laryngoscopy and intubation using the Airtraq(®) , Macintosh and McCoy laryngoscopes. Anaesthesia (2014) 1.93
Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) (1994) 1.93
Studies of prevalence of Japanese cedar pollinosis among the residents in a densely cultivated area. Ann Allergy (1987) 1.92
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet (1983) 1.92
Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use. Trans R Soc Trop Med Hyg (1979) 1.92
Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis (1998) 1.92
Acute delirium and functional decline in the hospitalized elderly patient. J Gerontol (1993) 1.91
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Two hundred glass injuries. Arch Dis Child (1984) 1.87
Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology (2010) 1.87
Analysis of change in self-reported physical function among older persons in four population studies. Am J Epidemiol (1996) 1.86
The actylation of sulamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther (1968) 1.85
Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis (1986) 1.84
Cognitive decline after hospitalization in a community population of older persons. Neurology (2012) 1.83
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Empirical, automated vocabulary discovery using large text corpora and advanced natural language processing tools. Proc AMIA Annu Fall Symp (1996) 1.81
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun (1984) 1.81
Social networks and disability transitions across eight intervals of yearly data in the New Haven EPESE. J Gerontol B Psychol Sci Soc Sci (1999) 1.79
Educational attainment and cognitive decline in old age. Neurology (2009) 1.78
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther (2001) 1.77
A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. Neuron (2000) 1.76
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74
The polymorphic acetylation of sulphapyridine in man. J Med Genet (1972) 1.72
A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology (2003) 1.71
Risk factors for delirium in hospitalized elderly. JAMA (1992) 1.70
Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol (2001) 1.70
Proneness to psychological distress and risk of Alzheimer disease in a biracial community. Neurology (2005) 1.70
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut (1972) 1.70